ACTG 076

ACTG 076

AIDS Clinical Trial Group Study 076. A study that validated the prophylactic use of AZT in HIV-infected pregnant women (HIPW), orally during pregnancy, IV during labor, and subsequently in newborns; decreased by 2⁄3 HIV-positivity in infants, saving 1 in 7 infants born to HIPW. The ACTG 076 protocol became the standard of care for these women.

ACTG 076

AIDS Clinical Trial Group Study 076 AIDS A study that validated the prophylactic use of AZT in HIV-infected pregnant ♀–HIPW, orally during pregnancy, IV during labor, and subsequently to newborns ↓ by23 HIV-positivity in infants, saving 1 in 7 infants born to HIPW; ACTG 076 is the standard of care for these ♀. See AIDS, HIV.
References in periodicals archive ?
The ACTG 076 clinical trials showed that mothers who received AZT treatment during the last two trimesters of pregnancy and whose babies then received AZT for six weeks after birth had an eight percent chance of transferring the HIV infection to the child, while those who were not treated had approximately a twenty-five percent chance.
18) After the release of the ACTG 076 study and the use of the AZT during pregnancy, the rate dropped forty-three percent between 1992 and 1996.
The landmark 1994 study known as ACTG 076 showed that a three-part regimen of zidovudine given to a patient during pregnancy and labor and to the infant for the first 6 weeks of life decreased the HIV transmission rate by 68%.
Since publication of the ACTG 076 trial, several studies have confirmed and extended these initial results (14,16-30).
In a study of pregnant women, ACTG 076, the estimated risk of mother-to-child transmission of HIV was less than 8% in zidovudine-treated infants (antenatal, perinatal, and neonatal drug administration) versus almost 25% in the placebo group.
In the developing world, where on average the annual health budget is approximately $10 per person, the complex ACTG 076 regimen, which costs approximately $1,000 per pregnancy, is simply not an option.
Data from the original ACTG 076 trial in the United States showed transmission to be 8 percent in the treated group compared to 25 percent in the placebo group, representing about 70 percent reduction in transmission risk.
In the study, known as ACTG 076, AZT therapy was initiated in the second or third trimester and continued during labor, and infants were treated for six weeks following birth.
However, the AZT regimen used in ACTG 076 is not always available because of cost and logistical demands.
These updated results, based on findings as recent as early September, support and extend the findings of the interim analysis announced in February when ACTG 076 was halted.
By assuming similar rates and applying the preliminary finding from ACTG 076 of a two-thirds reduced risk of transmission when both the pregnant women and their babies received therapy with Retrovir, the researchers concluded that this intervention could potentially prevent an estimated 1,200 babies from becoming infected at birth.
today issued the following statement in response to the data from study ACTG 076 which indicate that therapy with the company's antiretroviral medication Retrovir(R) brand zidovudine (AZT) reduces the rate of transmission of the human immunodeficiency virus (HIV) from mothers to their infants: